TC
HELP

Truvestments Capital’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Truvestments Capital’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16
Closed -$248 – 335
2024
Q1 		$248 Buy
+16
New +$231 ﹤0.01% 694

Other funds holding HELP

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Truvestments Capital's HELP Position: Q2 2024 in Review

Truvestments Capital sold out of Helus Pharma Inc. Common Stock (HELP) in Q2 2024, closing a stake of 16 shares — an estimated $248 sold.

Truvestments Capital first reported a position in HELP in Q1 2024 and held it in 1 quarter. The position peaked at $248 in Q1 2024. 98 funds tracked by Wall St. Rank hold HELP as of Q2 2024.

  • Truvestments Capital reported no remaining Helus Pharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Truvestments Capital sold 16 Helus Pharma Inc. Common Stock shares in Q2 2024, an estimated $248.
  • Truvestments Capital first reported a position in Helus Pharma Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Truvestments Capital's Helus Pharma Inc. Common Stock position peaked at $248 in Q1 2024.
  • 98 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q2 2024.

Based on Truvestments Capital's 13F filing for Q2 2024, filed 14 Aug 2024.